Beth Israel Deaconess Medical Center in Boston, Massachusetts is a teaching hospital of Harvard Medical School. It was formed out of the 1996 merger of Beth Israel Hospital and New England Deaconess Hospital . Among independent teaching hospitals, Beth Israel Deaconess Medical Center consistently ranks in the top three recipients of biomedical research funding from the National Institutes of Health. Research funding totals nearly $200 million annually. BIDMC researchers run more than 850 active sponsored projects and 200 clinical trials. The Harvard-Thorndike General Clinical Research Center, the oldest clinical research laboratory in the United States, has been located on this site since 1973. Wikipedia.
Medici D.,Beth Israel Deaconess Medical Center
Nature medicine | Year: 2010
Mesenchymal stem cells can give rise to several cell types, but varying results depending on isolation methods and tissue source have led to controversies about their usefulness in clinical medicine. Here we show that vascular endothelial cells can transform into multipotent stem-like cells by an activin-like kinase-2 (ALK2) receptor-dependent mechanism. In lesions from individuals with fibrodysplasia ossificans progressiva (FOP), a disease in which heterotopic ossification occurs as a result of activating ALK2 mutations, or from transgenic mice expressing constitutively active ALK2, chondrocytes and osteoblasts expressed endothelial markers. Lineage tracing of heterotopic ossification in mice using a Tie2-Cre construct also suggested an endothelial origin of these cell types. Expression of constitutively active ALK2 in endothelial cells caused endothelial-to-mesenchymal transition and acquisition of a stem cell-like phenotype. Similar results were obtained by treatment of untransfected endothelial cells with the ligands transforming growth factor-β2 (TGF-β2) or bone morphogenetic protein-4 (BMP4) in an ALK2-dependent manner. These stem-like cells could be triggered to differentiate into osteoblasts, chondrocytes or adipocytes. We suggest that conversion of endothelial cells to stem-like cells may provide a new approach to tissue engineering. Source
Stern R.S.,Beth Israel Deaconess Medical Center
New England Journal of Medicine | Year: 2012
A 50-year-old woman with bipolar depression presents with a widespread pruritic rash of 1 day's duration. She is afebrile and otherwise well. She has a history of childhood eczema and is allergic to sulfonamide antibiotics. Her medications include thyroxine daily, naproxen intermittently, and lamotrigine, which she began taking 3 weeks earlier. How should this case be evaluated and treated? Copyright © 2012 Massachusetts Medical Society. Source
Tsokos G.C.,Beth Israel Deaconess Medical Center
New England Journal of Medicine | Year: 2011
SLE is an autoimmune disease that predominantly affects women and typically has manifestations in multiple organs. Immune-system aberrations, as well as heritable, hormonal, and environmental factors, contribute to the expression of organ damage. Immune complexes, autoantibodies, autoreactive lymphocytes, dendritic cells, and local factors are all involved in clinical manifestations of SLE. Biologic therapies and small-molecule drugs that can correct the aberrant immune-cell function are being developed in the hope that they will be more effective and less toxic than current treatments. Copyright © 2011 Massachusetts Medical Society. Source
Beth Israel Deaconess Medical Center | Date: 2015-05-07
An MRI method includes: performing a first data acquisition block of a pulse sequence to acquire a first MR data from a plurality of slices of a subject during a period of fully recovered longitudinal magnetization within the plurality of slices disposed at different locations in the subject; performing a second data acquisition block of the pulse sequence including a magnetization preparation module followed by a recovery period and an imaging sequence executed during the recovery period, to acquire a second MR data from the plurality of slices during the recovery period; and generating a T1 map of the subject based on the first MR data and the second MR data, of the plurality of slices.
Beth Israel Deaconess Medical Center | Date: 2015-02-20
The invention features compositions and methods of using a dimeric inhibitor, e.g., A1-A1, to selectively target 2GPI in 2GPI/antibody complexes. The compositions can be administered to subjects (e.g., a mammal, such as a human) having or likely to develop APS, or one or more symptoms of APS, in order to treat or inhibit the disease or treat or reduce its symptoms. The inhibitors of the invention include two ligand-binding A1 modules, e.g., from ApoER2, connected by a flexible linker.